FTI Advances delivers scientifically rigorous, audit-ready Health-Based Exposure Limit (HBEL) assessments prepared by qualified toxicologists — accepted by EMA, FDA, WHO, and India's CDSCO.
Regulatory agencies including EMA, FDA, PIC/S, and WHO are explicit: HBELs — including ADE, PDE, and OEL values — must be derived by persons with adequate expertise and experience in toxicology and pharmacology, familiarity with pharmaceuticals, and hands-on experience in health-based exposure limit derivation. This requirement is now enshrined in India's revised Schedule M cGMP guidelines enforced by CDSCO.
In practice, qualification is demonstrated through academic credentials (postgraduate or doctoral degrees in toxicology, pharmacology, or related life sciences), professional certifications such as DABT (Diplomate, American Board of Toxicology) or ERT (European Registered Toxicologist), and a documented track record of HBEL derivations accepted by regulatory inspectors.
FTI Advances employs toxicologists meeting all these criteria, with experience spanning small molecule APIs, biologics, biosimilars, hormones, cytotoxics, oncology compounds, and genotoxic impurities. Our team has delivered over 5000 HBEL assessments for pharmaceutical clients in India, the USA, Europe, Southeast Asia, and the Middle East.
The revised Schedule M under the Drugs and Cosmetics Act has made HBEL derivation by a qualified toxicologist a mandatory GMP requirement for all multi-product pharmaceutical manufacturing facilities in India. CDSCO inspectors now routinely audit HBEL reports and verify the qualifications of the toxicologist who prepared them.
For pharmaceutical companies exporting to EMA or USFDA-regulated markets, the requirement is even more stringent. EMA's Q&A on health-based exposure limits (2018) requires that the qualified expert's credentials be documented in the supplier qualification file, and that HBELs undergo periodic review — typically every three years or when new toxicological data becomes available.
Choosing an unqualified provider — or one that uses template-based reports without genuine scientific assessment — risks receiving a critical GMP observation during an FDA Pre-Approval Inspection (PAI), EMA GMP audit, or WHO-GMP inspection. The cost of a rejected report, repeat validation, and regulatory delay far exceeds the investment in a qualified toxicologist from the start.
Our qualified toxicologist team in India provides the following HBEL and related services for pharmaceutical manufacturers:
Every HBEL report prepared by FTI Advances is simultaneously aligned with multiple regulatory frameworks, ensuring clients need only a single report for domestic and export compliance:
A complete HBEL report from FTI Advances includes: a structured literature search across multiple databases (PubMed, ToxNet, ECHA, regulatory agency submissions); systematic identification of the critical toxicological effect (point of departure); NOAEL/LOAEL derivation with full data tables; application and justification of all uncertainty factors (F1–F5); route-to-route correction where applicable; the final ADE/PDE/OEL value with units and regulatory citations; and the toxicologist's credentials and sign-off statement.
Reports are delivered in fully formatted, audit-ready PDF and Word format, with a cover page confirming the qualified toxicologist's credentials — meeting the supplier qualification documentation requirements of EMA Chapter 7 and WHO-GMP.
FTI Advances offers industry-leading turnaround times without compromising scientific rigour. Standard reports for well-characterised small molecule APIs are completed in 5–7 business days. Complex molecules, biologics, or those requiring extensive read-across analysis may take 10–15 business days. Expedited 48-hour service is available for urgent regulatory deadlines.
We also offer bulk molecule packages for pharmaceutical facilities requiring HBEL reports for 10 or more APIs — providing significant cost savings while maintaining individual molecule-specific scientific assessment for each compound.
FTI Advances offers a comprehensive range of services delivered by our qualified toxicologist India team. Whether you need ADE PDE toxicologist support for new molecule onboarding, outsource ADE India solutions for your cleaning validation programme, or HBEL calculation India for revised Schedule M compliance, our team covers every scenario. We also provide toxicological risk assessment India for genotoxic impurities, NOAEL LOAEL assessment for novel APIs, and cross contamination risk assessment for multi-product facilities.
Our pharmaceutical toxicology consulting India services are trusted by companies across Ahmedabad, Mumbai, Hyderabad, Pune, and across India. As a toxicology CRO Ahmedabad Gujarat, FTI Advances is uniquely positioned to serve both domestic Schedule M requirements and international EMA, FDA, and WHO-GMP compliance needs from a single, cost-effective source. We specialise in affordable PDE report India services with fast turnaround ADE report delivery — making professional toxicological compliance accessible to companies of all sizes.
For companies requiring ADE PDE OEL outsource India capabilities, FTI Advances provides fully managed outsourcing with supplier qualification documentation, confidentiality agreements, and direct toxicologist access. Our DABT ERT toxicology India qualified team ensures your reports meet the highest international standards while delivering at Indian CRO pricing — typically 40–60% less than equivalent European or US-based providers.
Selecting the right partner for health-based exposure limit derivation is a decision that directly impacts your regulatory standing. A qualified toxicologist in India must bring together formal academic training in toxicology or pharmacology, hands-on experience with pharmaceutical risk assessment, and a thorough understanding of guidelines issued by EMA, FDA, WHO, and CDSCO. At FTI Advances, every HBEL assessment is prepared and signed by a credentialed expert whose qualifications are fully documented — giving regulatory inspectors immediate confidence in the science behind your cleaning validation programme.
FTI Advances supports pharmaceutical manufacturers from API synthesis hubs in Hyderabad and Vadodara to formulation facilities in Pune, Mumbai, Baddi, and Chennai. Our team delivers audit-ready ADE, PDE, and OEL reports through a streamlined remote process — no site visit required. Clients across India have successfully navigated EMA GMP inspections, USFDA Pre-Approval Inspections (PAIs), and CDSCO Schedule M audits with HBEL documentation prepared by our expert toxicologists. When your facility needs a qualified toxicologist in India who understands both domestic compliance and international export requirements, FTI Advances delivers both in a single engagement.
Working with a qualified toxicologist in India through FTI Advances is designed to be efficient and transparent. You submit your API name, CAS number, and route of administration — and our toxicologist team takes it from there. A structured literature search is conducted across multiple regulatory and scientific databases, the critical effect and point of departure are identified, uncertainty factors are applied with individual scientific rationale, and the final ADE, PDE, or OEL value is calculated and documented in a complete, formatted report. Standard delivery is five to seven business days, and every report is signed by a senior qualified toxicologist whose credentials are included in your supplier qualification file — meeting EMA Chapter 7 and WHO-GMP requirements for contracted GMP services.
Submit your molecule for an ADE, PDE, or OEL assessment. Audit-ready reports accepted by EMA, FDA, WHO, and CDSCO inspectors.
Request Your Report Today →Complete HBEL solutions from India's qualified toxicologist team — for global pharmaceutical compliance.
Scientifically rigorous acceptable daily exposure and permitted daily exposure assessments per EMA and FDA guidelines.
Occupational exposure limit derivation for HPAPI, cytotoxics, hormones, and potent APIs — protecting manufacturing workers.
Maximum allowable carryover calculations linking HBEL values to cleaning validation acceptance criteria.
ICH M7(R2) assessment of mutagenic and carcinogenic impurities with TTC-based acceptable intake limits.
HBEL reports specifically structured for India's revised Schedule M cGMP requirements and CDSCO inspections.
Mandatory EMA Q&A 2018 review of existing HBEL assessments — updated with new toxicological literature.
Per EMA, PIC/S, and WHO guidance — and now India's Schedule M — a qualified toxicologist should have a postgraduate or doctoral degree in toxicology, pharmacology, or life sciences, documented experience in health-based exposure limit derivation, and preferably a professional certification such as DABT or ERT. FTI Advances' team meets all these criteria.
Yes. Our ADE, PDE, and OEL reports are structured to meet the requirements of EMA Guideline EMA/CHMP/CVMP/SWP/169430/2012, India's revised Schedule M, WHO TRS 1033, PIC/S PI 006, and USFDA cleaning validation guidance simultaneously. They have been accepted by inspectors from all these agencies.
Standard turnaround is 5–7 business days for well-characterised small molecule APIs. Expedited 48-hour service is available. Bulk packages (10+ molecules) are available with tiered pricing and priority scheduling.
No. FTI Advances prepares reports that simultaneously satisfy EMA, USFDA, WHO-GMP, and Schedule M requirements in a single document, reducing cost and simplifying your supplier qualification process.
Trusted and compliant with